Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $9.8 million.

  • Aclaris Therapeutics' Accumulated Expenses rose 10720.03% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 10720.03%. This contributed to the annual value of $20.3 million for FY2024, which is 456.13% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Accumulated Expenses of $9.8 million as of Q3 2025, which was up 10720.03% from $11.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' Accumulated Expenses' 5-year high stood at $20.3 million during Q4 2024, with a 5-year trough of $3.6 million in Q1 2021.
  • For the 5-year period, Aclaris Therapeutics' Accumulated Expenses averaged around $9.3 million, with its median value being $8.6 million (2025).
  • In the last 5 years, Aclaris Therapeutics' Accumulated Expenses skyrocketed by 12349.16% in 2023 and then crashed by 6885.22% in 2024.
  • Aclaris Therapeutics' Accumulated Expenses (Quarter) stood at $10.1 million in 2021, then dropped by 13.43% to $8.7 million in 2022, then soared by 123.49% to $19.4 million in 2023, then increased by 4.56% to $20.3 million in 2024, then plummeted by 51.88% to $9.8 million in 2025.
  • Its Accumulated Expenses was $9.8 million in Q3 2025, compared to $11.4 million in Q2 2025 and $8.6 million in Q1 2025.